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A Introduction 
 
1 Indirubin 
 
1.1 Chemical properties, occurrence and history  
 
Indirubin is a red coloured, structural isomer of the blue dye indigo. It is found in 
small amounts together with other indigoids. Plants like Isatis Indigofera, Indigofera 
tinctoria, Indigofera suffrutticosa and some others contain the precursors Indican or 
Isatan B which are transformed by oxidation and dimerization to Indirubin and its 
isomers during  the procession of the plant material [1]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I 
Formation of Indigo and Indigoids in plant material 
The colourless precursors Indican and Isatan B are deglycosylated by enzymatic or acidic hydrolysis 
into Indoxyl. Further oxidation in the presence of oxygen leads to Isatin. By spontaneous, non 
enzymatic dimerization Indigo, Isoindigo and Indirubin are formed.  
 
Scheme taken from Schwaiberger, A. [2] 
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 Indirubin was also found in the ancient dye "Tyrian blue", extracted from molluscs [3] 
Indirubin was found among other indigos as a product of Cytochrome P450 oxidation. 
CYP 2A6 was able to oxidise Indol to Isatin and Indoxyl, precursors of Indigoids. 
Indigo was also found at random in bacterial cultures, modified for expression of 
human Cytochrome P450. In this case, Indigo is believed to be syntesized as a 
breakdown product of tryptophan [4, 5]. Indirubin can be found in the urine of 
leukemia patients [6] and patients suffering from purple urine bag syndrome [7]. 
Indigo and Indirubin occur physiologically in small amounts as side product of 
tryptophan metabolism [8]. 
 
The name Indirubin was originally given to red coloured sideproducts of the Indigo 
synthesis in the 19th century. In western chemistry it was used in the dying industry 
to variate the intensity of indigo colour  [9, 10]. 
 
 
 
1.2 Medicinal use 
 
Indirubin was found to be the active ingredient of Danggui Longhui Wan, a recipe in 
Traditional Chinese Medicine (TCM) composed of 11 herbal medicines [11, 12]. 
 
In TCM praxis Danggui Longhui Wan has been used for a long time to treat cancer 
especially chronic myelotic leukaemia. Clinical trials with the mixture showed 
promising results also for several other forms of leukaemia. The active principle of 
this mixture was found in Qing Dai, a dark blue powder, prepared from the leaves of 
Baphicacanthus cusia (Acanthaceae), Poligonum tinctorium (Polygonaceae), Isatis 
indigofera (Brassicaceae), Indigofera suffrutticosa (Indigoferaceae) and Indigofera 
tinctoria (Fabaceae) [13] and could finally traced back to indirubin. 
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Figure II 
Use of Indigoids in Traditional Chinese Medicine 
Indigo naturalis (Qing Dai) is one component of the TCM recipe Danggui Longhui Wan, commonly 
used to treat chronic myelotic leukaemia. It contains Indigo as well as Indirubin which was investigated 
to be the active ingredient.  
 
Scheme downloaded from http://www.sb-roscoff.fr/ indirubin/intro.html 
1.3 Derivatives 
 
Because of the poor solubility of Indirubin itself [13], several derivatives were 
designed. Among them there are 5-halogeno-indirubin, N-ethyl-indirubin and 
Indirubin 3´-monoxime  [14-16]. Indirubin 3´-monoxime (I3MO), one of the few 
commercially availiable indirubin derivatives, shows better solubility and good 
antitumor activity together with low toxicity in animal models [13]. I3MO is the 
indirubin derivative used in this study. 
 
 
 
 
 
 
Figure III  
Chemical Structure of Indirubin 3´monoxime 
 
Scheme taken from Schwaiberger,A. [2] 
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1.4 Reported bioactivities of Indirubins 
 
Indirubin and its derivatives show a wide range of biological activities, many of them 
cell type specific. Most prominent in the literature are inhibition of kinases, anti-
inflammatory properties and activation of the aryl hydrocarbon receptor (AhR) by 
indirubins. 
 
1.4.1 Inhibition of Kinases 
 
Indirubin and derivatives can competitively replace ATP from its binding pocket and 
hereby inhibit kinase activity [13]. 
I3MO is reported to be an inhibitor for cyclin dependent kinases (CDK), namely 
CDK 1,2, 4 and 5 [13]. CDK inhibition by I3MO leads to often cell-type specific effects 
blocking the cell cycle either in late G1 or G2/M phase. In HBL 100 cells for example, 
I3MO leads to cell cylce arrest and endoreplication followed by necrotic cell death 
[17]. The potential to interfere with the cell cyle has drawn attention onto indirubin 
and its derivates for a possible use in health disorders with aberrant proliferation 
such as cancer. Inhibition of CDK5/p25 by I3MO may be beneficial in Alzheimer´s 
disease due to reduced phosphorylation and thus reduced activation of tau protein 
[18]. In this context, I3MO-mediated inhibition of another tau-kinase, namely GSK3β 
may be also of interest [18-20]. 
The glycogen synthase kinase (GSK)3-β is a widespread enzyme, first discovered 
in the regulation of insulin-induced glycogen synthesis [21]. It acts in the Wnt 
pathway, as explored in Xenopus laevis and Drosophila, via regulation of β-catenin 
and its downstream gene expression [22]. Also the apoptosis of dopaminergic 
neurons in Parkinson´s disease could be reduced by I3MO due to inhibiton of GSK3β 
[23]. 
7-Bromo-Indirubin-oxime is a potent inhibitor of Aurora Kinase B and C, members 
of a family of serine/threonine kinases involved in mitotic cell division processes. 
Since these kinases are overexpressed in most human cancer cells, their inhibition 
by indirubins may explain the successful use of indirubins in cancer therapy [24, 25]. 
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Indirubin-3´-monoxime is also known as inhibitor of Jun-N-terminal kinase (JNK), 
reducing c-Jun phosphorylation which has been reported to play a role in neuronal 
apoptosis [26]. 
The proliferation of NIH/3T3 cells is blocked by indirubin derivatives which was 
explained by specific inhibition of autophosphorylation of the receptor tyrosine kinase 
FGFR1 (Fibroblast growth factor receptor1) [27]. 
 
1.4.2 Anti-inflammatory activity 
 
Indirubin and its derivates show anti-inflammatory qualities in several studies. In 
human myelomonocytic HBL-38 cells, I3MO inhibited the production of IFNγ and in 
murine splenocytes it abolished the synthesis of IL-6, both known as inflammatory 
cytokines [28]. Studies using  the human bronchial epithelial H292 cell line infected 
with influenza virus could demonstrate that Indirubin and Indirubin-3´monoxime 
reduced the production of the chemokine RANTES (regulated on activation, normal t-
cell expressed and secreted). The virus-induced phosphorylation of the NFκB-
regulatory protein IκBα and the phosphorylation of the MAPK p38 was reduced in 
response to I3MO treatment [29].  
Studies suggest that at least a part of Indirubins anti-inflammatory effect is mediated 
via inhibition of the NFκB pathway [30]. 
 
1.4.3 Ligand of Aryl Hydrocarbon Receptor (AhR) 
 
Indirubin has further been reported to act as ligand and activator of the aryl 
hydrocarbon receptor [8] 
Although the endogenous ligand of AhR is not found yet, activated AhR (e.g. by 
exogenous ligands) has been identified to be involved in cellular differentiation [31] 
and expression of xenobiotic metabolizing enzymes like cytochromes P450 in 
response to e.g. dioxin or PCB´s [31-33].  Indirubin is known to induce CYP 1A1 and 
1B1 in human breast cancer cells through AhR [34]. 
Studies with indirubin derivatives, only capable of binding to AhR and not to kinases 
have shown that binding to AhR can suffice to induce a G1 phase arrest due to 
increased p27 expression, whereas cytotoxic effects of Indirubins are more related to 
kinase inhibition than to AhR activation [35]. 
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1.4.5 Other 
 
Indirubin derivatives are also reported to block STAT (Signal transducers and 
activators of transcription) signaling, which is found constitutively active in cancer 
cells. Treatment with Indirubin leads to decreased expression of antiapoptotic 
proteins Survivin and Mcl-1, inducing apoptosis [36]. 
Recently Indirubin-3´monoxime was shown to inhibit mitochondrial oxidative 
phosporylation. This indicates new mechanism of Indirubin on inhibiting the cell 
function [37]. 
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2 Atherosclerosis 
 
2.1 General overview 
 
Multiple processes may lead to the manifestation of atherosclerosis. Although the 
complete mechanisms are not fully understood yet, genetic predisposition as well as 
dietary and life-style habits, like smoking and alcohol are believed to be responsible 
for atherosclerotic diseases. 
 
Atherosclerosis describes abnormal indurations and lesions in the large (elastic) as 
well as in the medium (muscular) arteries. It is characterized as thickening of the 
intima in response to vascular intimal injury.  
 
Atherosclerosis is a disease that starts at an early age with clinically silent lesions, 
occurring at predisposed areas in large and medium sized arteries. Its later 
complications contribute to mortality more than any other desease in western world 
[38]. 
2.2 Physiology 
 
The typical arterial wall can be divided in three distinct tissues (tunicas): intima, 
media and adventitia. The innermost layer, next to the lumen is named the intima, 
consisting of a monolayer of endothelial cells, laid on a basement membrane, the 
internal elastic lamina. The media is composed of smooth muscle cells, providing the 
vasomotor tone. The vessel is completed by the adventitia, which is separated from 
the media by the external elastic lamina. The adventitia consists of loose connective 
tissue, fibroblasts and autonomic nerve endings. 
 
There are three types of arteries, which can be divided by their size and 
compostition.  
 
1. The large (or elastic) arteries contain a high amount of elastic fibers in the 
media, which are arranged in compact layers together with VSMCs.  
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2. The medium (or muscular) arteries contain fewer elastic material in their media 
and are smaller in size.  
 
3. The arterioles and the capillares together represent the smallest type of 
arterial vessels mainly found in tissue and organs.  
 
Atherosclerosis affects only the large and the medium sized arteries. It seems that 
there are predominant arteries like the aorta or the corona, which are very prone to 
atherosclerotic events, whereas other vessels are relatively safe. This might be in 
relation to shear forces and turbulent blood flow which are events that expose parts 
of the vessels to vascular injury [38]. 
 
 
 
 
 
 
 
 
 
 
 
Figure IV 
Anatomy of the Arterial wall  
 
Scheme downloaded from: 
http://journals.cambridge.org/fulltext_content/ERM/ERM4_01/S1462399402004039sup005.pdf 
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2.3 Pathological events that lead to atherosclerosis 
 
At an early stage of the disease, it is believed that the monolayer of endothelial cells, 
which belong to the intima of the arteric vessel becomes injured e.g. by hypertension, 
aberrantly high lipids, metabolites of cigarette smoke or shear forces. This results in 
inflammation, endothelial cell activation and increased endothelial permeability 
leading to lipoprotein accumulation as well as adhesion of monocytes and of 
platelets. Monocytes then begin to emigrate into the intima, develop into 
macrophages and engulf accumulated lipids, leading to the formation of “foam” cells. 
The result is a so called "fatty streak", an early stage of an atherosclerotic lesion 
which is clinically silent.   
 
Vascular smooth muscle cells from the media then begin to migrate towards the 
intima and begin to proliferate, a process induced by growth factors and cytokines. 
Platelet-derived Growth Factor (PDGF) is the most important stimulus for proliferation 
and migration of VSMCs [39]. Also FGF is reported to act as a mitogen and 
chemoattractant and to a smaller extent IGF-1, TGFβ and EGF [40]. These mitogens 
are derived from accumulating platelets, macrophages and lymphocytes on the site 
of the inflammation as well as from VSMCs themselves and intimal endothelial cells. 
VSMCs also engulf lipids and synthesize extracellular matrix. This process 
contributes to the narrowing of the vessel.  
 
As the atherosclerotic process continues, cells in the center of the atherosclerotic 
plaque get necrotic and form a core consisting of disorganized lipds and dead cell 
material. VSMCs form a fibrous cap that covers this core, resulting in a fibrofatty 
atheroma.  
 
Ongoing inflammation, shear forces as well as activity of metalloproteases and 
collagenases, however, render the atheroma prone to rupture. The break can lead to 
formation of a thrombus which on the one hand can be carried away by the blood 
stream to cause ischaemic events elswhere, or on the other hand contribute to the 
deteriorated narrowing of the vessel. [38] 
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Figure V 
Formation of a plaque 
Through inflammation, migration and proliferation of VSMCs, accumulation of platelets, macrophages 
and lymphocytes and incorporation of lipids a plaque is forming which leads to narrowing of the vessel 
and reduction of blood flow. 
 
Scheme downloaded from:  
http://www.web-books.com/eLibrary/Medicine/Cardiovascular/Atherosclerosis.htm 
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2.4 Therapeutic options 
 
The best therapy of atherosclerotic diseases is primary prevention of avoidable risk 
factors. Physical workout/exercise and dietary measures can reduce lesions at an 
early stage. Also several drug-mediated interventions, e.g. to lower the cholesterol 
level, a major risk factor for atherosclerosis, are implicated [39]. After a plaque has 
been formed, several surgical methods like balloon angioplasty (also PCTA) 
accompanied by stent placement, transplantation of vessels and bypasses can be 
done, but ironically these procedures themselves lead to restenosis (see next 
chapter) and inflammation of the vessel [41].  
 
2.5 Restenosis 
 
Restenosis, i.e. the renarrowing of the vessel, is a major problem for patients 
undergoing a PTCA (percutaneus transluminal coronary angioplasty). About 20% of 
all patients develop it. The processes that lead to restenosis are similar to those,  
involved in the genesis of atherosclerosis. Due to inflammatory processes, driven by 
endothelial injury during balloon inflation or stent placement, proliferation of VSMCs 
and therefore narrowing of the vessel is caused. In contrast to the atherosclerotic 
plaque, restenosis shows a diffuse and symmetrical narrowing, affecting long parts of 
the vessel [39]. 
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Figure VI 
Illustration of PTCA and of Restenosis 
The processes that lead to restenosis are almost the same involved in the genesis of atherosclerosis. 
Restenosis is a major problem in therapy of vascular narrowing, attending 20% of all patients. 
 
Scheme downloaded from 
http://www.heart.org.in/dieseases/images/stent_restenosis.gif 
 
In current restenosis therapy, drug eluting stents are in use. In contrast to common 
metal stents, they are coated with a polymer, eluting antiproliferative drugs like 
Sirolimus or Paclitaxel. These coated stents show a reduction in restenosis rate in 
animal models and in clinical trials [42, 43].  
 
Although these stents are of great advantage, several drug-related side effects 
shorten the therapeutic benefit. Sirolimus, a immunmodulating drug, is reported to 
cause thrombosis and reduce wound healing ability [44]. Paclitaxel shows cytotoxic 
effects common for anti-mitotic agents [45, 46].  
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3 PDGF 
 
The platelet-derived growth factor (PDGF) was originally found in platelets, but all 
vessel cells seem capable of expressing it. It is a cytokine that was primarily 
discovered as the active factor leading to proliferation and migration of smooth 
muscle cells of apes [47]. PDGF and its elicited downstream signalling is now 
accepted to be the most predominant stimulus involved in the activation, migration 
and proliferation of vascular smooth muscle cells. PDGF is related to diseases like 
atherosclerosis [48] but several other vascular effects of PDGF stimulation are 
reported. Its importance may be highlighted by the fact that the embryonal 
development of mice can be severely influenced when knocking out either the A 
chain of PDGF or its α receptor subunit or the B chain or β receptor subunit [49-51]. 
Also an effect on wound healing [52], regulation of the fluid pressure [53] and a 
PDGF-BB-specific effect on NO-mediated relaxation of blood vessels [54] were 
reported. PDGF from platelets may play a role in a feedback mechanism controlling 
platelet aggregation [55, 56]. 
 
3.1 Structure and binding properties 
 
The PDGF molecule consists of two isomeric protein chains, which are synthesized 
as precursor molecules and processed via proteolysis. The mature chains consist of 
about 100 amino acids residues and have approximately 60% of their residues in 
common [57-61]. There are several isoforms of these chains, with the A and the B 
isomer being the most predominant, which can form homo- (AA, BB) or heteromeric 
(AB) dimers. Recently, a PDGF C and a PDGF D isomer were discovered, but yet 
little is known about their activity and distribution [62]. The PDGF AB heterodimer 
was only found in human platelets so far. It seems, that homodimers are the 
dominant appearance form of PDGF dimers. 
 
The detailed structure of PDGF was revealed by crystal structure analysis, showing 
that 6 cysteine residues form disulfid bonds. Three of these cysteine residues are 
involved in intrachain bonds forming a knot structure, while the remaining two 
cysteine residues form interchain bonds connecting the subunits of PDGF. PDGF 
shows similarity to the vascular growth factor [60]. The knot structure of the PDGF is 
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surrounded by two long β-sheet chains (loop 1 and 3) pointing in one direction and a 
smaller chain (loop 2) pointing to the other direction. The subunits of PDGF are 
assembled in an antiparallel manner and therefore loop 1 and 3 of the first subunit lie 
next to loop 2 of the other subunit [63, 64]. 
 
3.2 Structure of the PDGF receptor (PDGFR) and ligand-induced 
autophosphorylation 
 
PDGF binds to its own receptor, which again exists in two isomers, the alpha 
(PDGFRα) and the beta (PDGFRβ). In the inactive state the PDGFR subunits are 
separated from each other. Like for other members of this family of tyrosine kinase 
receptors, PDGF-R undergoes dimerization upon ligand binding. The monomers in 
the membrane are then bound together by the extracellular ligand. Thereby the α 
isoform is capable of binding the A or the B monomer of PDGF while the β subunit is 
only capable of binding the B monomer. Like this, the AA and the AB isomers of the 
PDGF are only capable of binding and activating the αα receptor and only the BB 
isomer can activate all isomers of the PDGF receptor. These data are mainly based 
on in vitro studies, but yet few information is available about the real in vivo situation.  
 
 
 
 
 
 
 
 
 
 
 
Figure VII 
In vitro ability of PDGF dimers to bind to the different PDGF Receptor isoforms 
The α chain of the PDGFR is able to bind PDGF A,B,C,D whereas the β chain of the PDGF is only 
capable of binding the PDGF B and D.  
 
Scheme taken from Andrae  [47] 
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When bound together on the PDGF molecule the receptor monomers are brought 
into a close proximity to each other, resulting in mutual autophosphorylation on 
several tyrosine residues. Thereby the intrinsic kinase activity of the assembled 
receptor plays a major role. Mutation of the Y857 residue, located in the kinase 
domain of the PDGF receptor leads to reduced kinase activity. The intercellular part 
of PDGF contains 15 tyrosine residues and 11 of them are known as 
autophosphorylation sites [65, 66]. 
3.3 Signal transduction 
 
The phosphotyrosines on the cytosolic part of the PDGF receptor constitute specific 
docking sites for effector molecules with a Src-homology (SH) domain. Once 
recruited to the receptor these effector molecules can regulate the kinase activity of 
the receptor, recruit other effector molecules via SH3 or PH (pleckstin homology) 
domains and like this stepwise transduce the signal further downstream. 
3.4 Important Intracellular Pathways, activated by PDGF  
 
3.4.1 MAPK Kinase pathway 
 
The activation of the MAP Kinase pathway starts with the activation of RAS [67-69]. 
Ras is a small GTPase and underlies a tight regulation through the GAP (GTPase 
activating protein) on the one hand and the GEF (guanine nucleotide exchange 
factor) SOS1/Grb2 complex on the other hand. Sos1 forms a complex with Grb2, a 
SH2 domain protein that binds to the phosphorylated PDGFR directly or via adaptor 
proteins, and converts RAS GDP to RAS GTP and therefore activates it [67]. The 
activation of RAS leads to activation of Raf-1 a serin/threonin kinase and the first 
kinase in a line of kinases followed by MEK 1,2 and then by the MAP kinases 
ERK1,2. Further signalling leads to various cellular effects, among them the 
expression of several gene products like  c-myc, c-fos, c jun [70-73]. After docking to 
the PDGF receptor on Y771, GAP hydrolyses RAS GTP to RAS GDP, therefore 
inactivates RAS and terminates the signal. 
Similar pathways lead to the activation of p38 MAPK and JNK Kinases. It has been 
shown that the activation of p38MAPK is related to vascular injury [74]. 
20 
 
Downregulation of JNK prevented sucessfully neointima formation in ballon catheter 
injured arteries of rats [75]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure VIII 
MAPK Kinase pathway 
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3.4.2 PI3K/AKT Pathway 
 
PDGF stimulation leads to activation of the PI3K/AKT pathway [76, 77] that is linked 
to cell cycle progression and proliferation [78].  
 
Phosphoinositide kinases (PI3K) are a family of enzymes, capable of phosphorylating 
phosphatidyl inositole bisphosphate in their 3´position. PI3K binds to the activated 
PDGF receptor with its regulatory subunit p85 on tyrosine residues Y740 and Y751. 
After binding to the receptor, PI3 Kinase is phosphorylated at Y508 in the regulatory 
subunit. PI3K is in complex with a catalytic subunit p110 which is responsible for 
converting phosphatidylinositole (4,5) bisphosphate into phosphatidyl inositole (3,4,5) 
triphosphate = PI(3,4,5)P3 [79].  
 
PI(3,4,5)P3 is able to interact with proteins bearing a PH (pleckstin homology) domain 
[76, 77]. PI(3,4,5)P3 is interacting with the PH domain on AKT (also referred as Protein 
Kinase B), leading to recruitment of AKT to the inner cell membrane [80-82]. 
 
The activation of AKT via PI3K is also regulated by PI(3,4,5)P3. It activates PDK1 and 
PDK2 kinases which in turn phosphorylate AKT on a threonine T308 and a serine S473 
residue. Phosphorylation of both residues is required for maximal activation of AKT 
leading to detachment from the inner membrane towards the nucleus. [79, 83] In 
contrast, the phosphatases PTEN and SHIP are responsible for degrading PI(3,4,5)P3 
into PI(4,5)P2 and PI(3,4)P2 and therefore acting as negative controllers of this pathway 
[84-86]. 
 
AKT itself is involved in the regulation and activation of a great number of pathways 
leading to cell growth and proliferation. Phosphorylation by AKT leads to activation or 
often inhibition of its target proteins. Examples of AKT targets are the Forkhead-
related transcription factors and the glycogen synthase kinase-3 (GKS-3) and the 
CDK inhibitors p21CIP1 and p27Kip1 [84, 87]. 
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Figure IX 
PI3K / AKT Kinase pathway 
3.4.3 SRC Kinase pathway 
 
The Src family of tyrosine kinases, consisting of nine members in total, is well known 
to be involved in transducing the mitogenic PDGF signal, as several studies with 
blocking of Src showed [88-90]. 
 
The Src Kinase structure shows an N-Terminal half with a membrane targeting 
sequence, a unique domain (which differs among the members of SRC family) and a 
SH2 and SH3 domain. The C-Terminal half consists of a catalytic domain, and a 
short amino acid sequence, involved in regulation of activity. Y527 in the C-Regulatory 
region are important for regulation of activity. If Y527 is phosphorylated, the SH2 
domain on the N-Terminus is binding intramolecularly to pY527 (autoinhibition). 
Dephosphorylation of Y527 by a phosphatase is leading to activation, the SH2 domain 
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is free to interact with other phosphotyrosines such as in the activated PDGF-R. 
Autophosphorylation of Y416 stabilizes the active state [88]. 
 
Src Kinase is part of many promitogenic signalling cascades. Interruption of this 
cascades by the Src inihibitor SU6656 [88] stops PDGF induced protein synthesis 
and proliferation.  
3.4.4 JAK/STAT Pathway 
 
In contrast to other signalling pathways like the MAPK cascade, only two intracellular 
molecules are involved in transmitting the signal from the membrane to the DNA in 
the JAK/STAT pathway. It can be activated by cytokines like interferons or 
interleukines as well as growth factors like PDGF or EGF. Oxidative stress is also in 
discussion to activate Jak/Stat signalling [91-93]  
 
 
Figure X 
JAK / STAT Pathway 
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3.4.4.1 JAK Kinases 
 
The family of JAK consists of 4 members, the JAK1, JAK2, JAK3 and TYK2. They 
are involved in cytokine signalling. In contrast to growth factor signalling, cytokine 
receptors lack an intrinsic tyrosine kinase domain. Cytokines binding on a cytokine 
receptor lead to dimerization and receptor bound JAK get close enough to trans-
phosphorylate each other. This provokes an intramolecular change in JAK molecule, 
enabling the JAK to phosphorylate STAT transcription factors [91, 92, 94]. JAK is 
also reported to be activated by PDGF tyrosine kinase, but it is unclear if this is of 
importance in activating the STAT signal [93, 95, 96].  
 
JAK are negatively controlled via supressors of cytokine signalling (SOCS). The 
synthesis of these proteins is cytokine-induced and they act negatively on signalling 
pathways in different ways. Described actions are binding to phosphorylated tyrosine 
residues via SH2 domains and therefore inhibition of signalling, or blocking signal 
molecules via binding to their N-Terminus. Also a induction of proteasome- 
associated degradation is reported [97]. Also SHP-1, a phosphatase is involved in 
dephosphorylation of JAK and receptor tyrosin kinases.  
3.3.4.2 STAT Transcription factors 
 
The signal transducers and activators of transcription (STAT) represents a family with 
at least seven members: STAT 1, STAT 2, STAT 3, STAT 4, STAT 5A, STAT 5B, 
STAT 6, STAT 1β, STAT 3β. The expression and the function are highly tissue-
specific. They were first discovered in the context of interleukin signalling [98]. 
 
STAT transcription factors are activated by phosphorylation of a highly conserved 
tyrosine Y705 residue in the C-terminal near transactivation domain [99, 100]. There is 
evidence that also phosphorylation of a Serin S727 residue, present in some members 
of the STAT family is necessary to provide full activity of STAT [91]. 
 
STAT molecules were also found to bind to the PDGF receptor with their SH2 
domain. [101]. 
 
25 
 
After activation, STAT molecules form homo- or heterodimers in a way that the 
phosphotyrosine of the transactivation domain of one molecule lies next to a N-
terminal SH2 domain of the second molecule of the dimer complex. STAT dimers 
translocate into the nucleus and bind to specific promotor regions on the DNA [98]. 
 
There is evidence, that the process of dimerization, activation and internalisation into 
the nucleus differs within the family of STAT. Some STAT isoforms are constitutively 
present in the nucleus, others already exist as stable homodimers before being 
activated. However, the resulting change in DNA transcription and protein synthesis 
upon activation remains [102-106]. 
3.4.4.2 Regulation of STAT transcription factors 
 
Negative regulation of STAT-mediated signalling is done by protein inhibitors of 
activated STAT (PIAS). They act either on the DNA binding region of the STAT dimer 
or indirectly by suppressing DNA transcription. Another mechanism of regulating the 
STAT activity is dephosphorylation of the STAT dimer by protein phosphatases like 
TC-PTP [106]. 
3.5 Distribution 
 
Distribution and concentration of PDGF is variable in different tissues. As mentioned 
above, in embryonal tissue PDGF plays a crucial role in growth signalling. In normal 
tissue, there is often almost no detectable amount of PDGF, but e.g. inflammation 
can lead to a high increase. 
 
 
 
 
 
 
Table I: Causes of increased level of PDGF in tissue [107] 
 
Cause increased PDGF isoform 
high blood pressure PDGF A ↑ 
nervous contraction of vessels PDGF A ↑ 
shear stress PDGF A/B ↑ 
hypercholesteremia PDGF A/B ↑ 
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4 ROS 
 
Reactive oxygen species (ROS) are highly reactive chemical derivates of oxygen, 
which have different functions in cells. The highest concentration of ROS can be 
found in phagocytes, where they act in immunodefense by destruction of 
incorporated bacteria and germs, but in lower doses ROS can be found in almost 
every cell, where they act as second messengers for extracellular stimuli [108-110]. 
4.1 Oxidative Stress and Antioxidants 
 
Due to their high reactivity, ROS are a latent danger for the cell itself. Therefore 
several defense mechanisms are present to transform ROS into non dangerous 
species. An imbalance between the ROS level and the capability of degrading them, 
leads to oxidative stress, leading to damage of DNA as well as of intracellular 
structures [111]. 
 
Several enzymatic mechanisms are able to degrade and to detoxify ROS. Among 
them are the superoxide dismutase (SOD), catalase and glutathion peroxidase [108, 
112, 113]. Furthermore a large number of nonspecific substances like vitamin C, 
vitamin E, polyphenols are able to bind and inactivate ROS. As these substances are 
found in a broad variety of food, an appropriate diet can relieve oxidative stress. 
4.2 ROS Species 
 
There are several forms of oxygen derivates. Among them are radical species like 
the superoxide anion and stabile oxygen derivatives like hydrogen peroxide. 
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Type of Oxygen Forms Formula Name 
radical species O2ׁ- superoxide radical 
OHׁ hydroxyl radical 
ROOׁ peroxy radical 
ROׁ 
 
alkoxy radical 
stabile oxygen derivates H2O2 hydrogen peroxide 
ROOH hydroperoxide 
O3 ozone 
OCl- hypochlorous anion 
Table II: Types of Oxygen molecules 
 
Among them, the O2ׁ- superoxide radical is the primal source of ROS, from which 
other species can be derived.  
4.3 Genesis of ROS  
 
In VSMCs, ROS are produced intracellularly mainly by the NADPH oxidase enzyme 
complex [108, 109], which is located at the cell membrane and assembled out of 
several subunits. The catalized reaction is a transfer of electrons from NADPH to 
elementar oxygen.  
 
NADPH + 2O2      NADP+ + H++ 2O2
.- 
 
 
In the resting state NADPH oxidase consists of a membrane bound subunit, the b558 
complex, and three cytosolic compounds: p47phox, p67phox and p40phox. The b558 
membrane bound complex consists of two different subunits, gp91phox(=NOX2) and 
p22phox [108, 109, 111]. 
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Figure XI 
Assembly of a representative NADPH Oxidase containing the NOX 2 protein 
The NADPH oxidases form superoxide by transferring an electron from NADPH coenzyme to Oxygen.  
 
Scheme taken from Dworakowski, R. [114] 
 
The activation of NADPH oxidases, e.g. upon stimulation with a growth factor, starts 
in most cases with phosphorylation of p47phox and the recruitment of the cytosolic 
subunits towards the membrane where they assemble with the b558 complex. 
Furthermore Rac, a small GTPase binds to the complex [115]. 
 
The NOX family consists of several isoforms that are differentiated by the gp91phox, 
part of the b558 Complex. Gp91phox found in phagocytes is named NOX2. 
 
There are also some other sources of ROS in the cell like mitochondrial respiratory 
and enzymatic reactions, but in these reaction chains, ROS are only sideproducts.  
4.3.1 Distribution of NOX 
 
NOX proteins were first found in phagocytes, where they provide the highly oxidative 
environment, necessary for immunodefence, but later several other Nox isoforms 
(isoforms of gp91phox subunit) were discovered. Their distribution varies: 
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Nox Isoforms (gp91phox) Found in: 
NOX 1 Colon, Smooth Muscle Cells, Uterus, Prostate, Kidney, 
Stomach, Osteoclasts 
NOX 2 Phagocytes 
NOX 3 Inner ear 
NOX 4 Kidney, Smooth Muscle Cells, Endothelial cells 
NOX 5 Testis, spleen, Smooth Muscle Cells 
Table III: Distribution of NOX isoforms  [108, 116] 
 
NOX 5 has a different structure lacking p22phox, and is therefore only activated by 
Ca2+ release [111]. 
 
The exact function of each NOX isoform is not clearly known yet, but the different 
tissue distribution and activity suggests a highly specified function of each subtype in 
cell signalling [108]. 
 
In vascular cells the most predominant isoforms are NOX1 (VSMC), NOX2 
(endothelial cells) and NOX4 (VSMC and endothelial cells). The amount and activity  
of NOX proteins in vascular cells is sensitive to the influence of growth factors like 
EGF, PDGF, angiotensin II and insulin, mechanical forces like shear stress and the 
presence of metabolic factors like free fatty acids or lipids. 
4.4 Impact of ROS levels on cellular processes 
 
Aside of their well known use in host defense, Nox-derived ROS act in signal 
transduction and have been discovered to have multiple and often contradicting 
effects on cells, tissues and physiologic parameters. ROS are usually associated with 
inflammation, but also influence anti inflammatory processes.  
 
An important crosstalk between the nitrogenous system and ROS is the inactivation 
of NO by superoxide. The reaction of superoxide with NO leads to the formation of 
peroxinitrite, causing a diminished vascular relaxation and higher tonus [108]. 
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ROS furthermore interact with redox-sensitive cysteine residues on proteins and 
enzymes and hereby modulate their activity. Cysteine-oxidation of protein tyrosine 
phosphatases, a class of enzymes that inactivate intracelluar messengers by 
removing phosphate residues, gives ROS a wide influence on activation and 
inactivation of intracelluar signalling cascades such as MAPK (see also next 
chapter). It also has an influence on the gene expression, by altering the 
phosphorylation status of transcription factors, leading to altered expression of e.g. 
TNFα, TGFβ1, AngII.  
 
ROS are reported on the one hand to trigger senescence and/or apoptosis either 
directly by damaging proteins, DNA and lipids or more indirectly by altering 
phosphorylation of apoptotic signalling molecules. 
 
On the other hand proliferation, induced by mitogens such as PDGF and angiotensin, 
depends on an increased level of ROS which is needed to activate kinases or 
inactivate phosphatases and hereby to transmit the signal further downstream. PI3K 
plays a crucial role in mediating the PDGF-induced ROS production [115], acting on 
Rac1, a GTPase downstream of PI3K and subunit of Noxes [110]. 
 
The question remains, why there are so many and also contradicting effects of ROS. 
It is believed that the different species of ROS, their distinct localization within 
tissues, cells and compartments, their different sources as well as duration and the 
strength of the ROS signal lead to this great variety of effects. 
 
4.5 Regulation of PDGF-R signalling by ROS and phosphatases 
 
As mentioned above, PDGF-R phosphorylation and subsequent signalling are 
controlled by the phospho-tyrosine phosphatases (PTP). This protein family is known 
to de-phosphorylate specific tyrosine residues and therefore inhibit the recruitment of 
effector molecules to the activated receptor. Therefore, after the binding of a ligand 
on the PDGF receptor, the activity of the PTPs has to be transiently suppressed in 
order to allow initiation of the signalling cascade. Hereby ROS play a crucial role.  
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In PDGF-related signalling, PTP 1β, PTEN, SHP-1 and SHP-2, DEP and TC-PTP are 
involved [112]. All of these PTPs bear a cysteine residue in their catalytic center 
which is sensitive to oxidation. After dimerization of the PDGF receptor, PI3K is 
docking on phosphorylated tyrosines with its p85 subunit, activating Rac and thus 
increasing Nox –derived ROS production.  Thus, upon PDGF stimulation there is an 
immediate increase of ROS which leads to inactivation of phosphatases. Like this, 
receptor phosphorylation can be maintained till the initial signalling steps have 
occurred. 
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5 Specific background and aim of this work 
 
 
 
 
Previous work in the lab had identified I3MO as promising compound to interfere with 
PDGF-mediated proliferation of VSMC in vitro. In vivo, I3MO could also reduce 
proliferation in a cuff induced neointimal formation model. I3MO could thus serve as 
a novel lead structure for stent-coating drugs. 
Concerning the molecular mode of action I3MO had been found to selectively block 
phosphorylation of STAT3 without affecting MAPK and AKT upon PDGF stimulation 
and to dampen PDGF-receptor phosphorylation (PhD thesis Andrea Schwaiberger) 
[2]. The detailed molecular mechanism how I3MO is mediating these effects 
remained unresolved. 
 
The aim of this work was to:  
 
1) confirm previous key findings, that 
  
a. Indirubin 3´monoxime is not affecting the PDGF induced 
phosphorylation of MAPK Kinases  ERK1,2 and AKT. 
b. Indirubin 3´monoxime has an influence on PDGF-induced receptor 
phosphorylation. 
 
2) investigate the possible role of ROS in the action of  I3MO on PDGF signalling 
since STAT3 phosphorylation is highly redox sensitive. 
 
3) check  whether antioxidants can mimic the effect of I3MO. 
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B MATERIALS AND METHODS   
 
1 MATERIALS   
 
All chemical substances were obtained from Sigma Aldrich (St. Louis, MO, USA), 
Fluka (Buchs, Switzerland) or Carl Roth (Karlsruhe, Germany) unless otherwise 
noted.  
 
1.1 Cell culture media and reagents  
 
Name Provider 
Dulbecco´s Modified Eagle Medium 
(DMEM) 4.5 g/L glucose,  
w/o L-glutamine, w/o phenol red  
 
Lonza Group Ltd. (Basel, Switzerland)  
 
Penicillin/streptomycin mixture  
(10,000 U/ml potassium penicillin/   
10,000 μg/ml streptomycin sulphate)  
 
Lonza Group Ltd. (Basel, Switzerland)  
 
L-glutamine 200 mM Lonza Group Ltd. (Basel, Switzerland)  
 
Trypsin (1:250) Invitrogen (Carlsbad, CA, USA) 
Calf serum Lonza Group Ltd. (Basel, Switzerland)  
 
Table IV: Cell culture reagents  
 
Calf serum was heat-inactivated (30 min, 56°C), aliquoted and stored at -20°C.  
 
1.2 Growth factors and cytokines  
 
Name Provider 
Recombinant PDGF-BB, human Bachem (Weil am Rhein, Germany) 
Table V: Growth factors and cytokines  
 
Lyophilized PDGF-BB was dissolved in sterile aqua bidest. to a concentration of 0.1 
μg/μl and further diluted in sterile PBS + 0.2 % BSA to a final concentration of 10 
ng/μl. Aliquots with 20 μl were stored at -20°C and prior to experiments diluted with 
DMEM to a final concentration of 1 ng/μl. For stimulations 20 ng/ml PDGF-BB were 
used.  
 
1.3 Indirubin-3´monoxime 
 
I3MO was provided by Laurent Mejer (CNRS, Roscoff, France). It was dissolved in 
DMSO and stock solutions of 10 mM were stored in aliquots at -80°C.   
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1.4 Antibodies  
 
Target Source Dilution Provider 
Phospho Akt S473 Rabbit 1:1000 New England Biolabs 
(Beverly, MA, USA) 
Phospho Erk1/2 T202/Y204 Rabbit 1:1000 New England Biolabs 
(Beverly, MA, USA) 
Phospho p38 T180/Y182 Rabbit 1:1000 New England Biolabs 
(Beverly, MA, USA) 
Phospho PDGF-R β Y579/581 Rabbit 1:1000 Biosource  
(Camarillo, CA, USA) 
phosphoSrc Y418 Rabbit 1:1000 Biosource  
(Camarillo, CA, USA) 
Phospho STAT3 Y705 Rabbit 1:1000 New England Biolabs  
(Beverly, MA, USA) 
α-Tubulin Mouse 1:1000 Santa Cruz, CA, USA 
Phospho tyrosine  
(P-Tyr-100) 
Mouse 1:1000 New England Biolabs  
(Beverly, MA, USA) 
Table VI: Primary antibodies  
 
Target Source Dilution Provider 
Rabbit IgG Goat 1:2500 New England Biolabs  
(Beverly, MA, USA) 
Mouse IgG  Goat 1:2500 Upstate  
(Charlottesville, VA, USA) 
Table VII: Secondary, HRP-linked antibodies  
 
Antibodies were diluted as stated above in TBS-T and if recommended by the 
provider, prepared with 5 % BSA or 5 % milk powder.  
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1.5 Solutions  
 
Cell Culture solutions  Used Reagents 
Growth Medium 500 ml DMEM 
 10% Calf Serum 
 100 U/ml / 100µg/ml Penicillin/Streptomycin 
 2 mM L- Glutamine 
CS-free medium 500 ml DMEM 
 100 U/ml / 100µg/ml Penicillin/Streptomycin 
 2 mM L- Glutamine 
PBS 8.0 g NaCl 
 0.2 g KCl 
 1.15 g Na2HPO4 
 0.2 g KH2PO4 
 0.1 g MgCl2 . 6H2O 
 0.1 g CaCl2 . 2H2O 
 ad 1000 ml Aqua dest. 
Trypsin/EDTA in PBS 0.05% Trypsin 
 0.02% EDTA 
 
Solutions Western 
Blotting 
  
Lysis buffer (stock 
solution) 
50 mM HEPES 
 50 mM NaCl 
 50 mM NaF 
 10 mM Na4P2O7 . 10H2O 
 5 mM EDTA 
 1 mM Na3VO4 
  in Aqua dest. 
 The reagents were dissolved in 325 ml 
H2O (4° C), adjusted to pH 7.5 with 
NaOH and filled up to a final volume of 
430 ml. 
- prior to use 4.3 ml Stock Solution 
 50 µl PMSF 0.1M 
 202 µl Complete 25x 
 500 µl TRITON X-100 
(10%) 
SDS Sample 
Buffer  
(stock solution) 
37.5 ml TRIS-HCl Solution 
0.5M pH 6.8 
 6.0 g SDS 
 30.0 g Glycerol 
 15.0 g Bromophenol blue 
 ad 1000 ml Aqua dest. 
-prior to use (3x 
solution) 
85% Stock solution 
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 15% 2-Mercaptoethanol 
 For 1x solution the appropriate amount 
of H2O was mixed with 3x solution.  
Electrophoresis 
buffer 5x 
15.0 g TRIS-base 
 72.0 g Glycerine 
 5.0 g SDS 
 ad 1000 ml Aqua dest. 
Blotting buffer 5x 15.17 g TRIS-base 
 72.9 g Glycine 
 ad 1000 ml Aqua dest. 
- prior to use 200 ml 5x Blotting buffer 
 200 ml MeOH 
 600 ml Aqua dest. 
TBS-T pH 8.0 3.0 g TRIS-base 
 11.1 g NaCl 
 1 ml Tween-20  
(add after adjusting 
pH) 
 ad 1000 ml Aqua dest. 
PMSF 0.1 M PMSF 
  in Isopropanol 
Complete 25x  
(Roche 
Diagnostics, 
Penzberg, 
Germany) 
one tablet  
2ml Aqua dest. 
Resolving gel 10% 5 ml PAA solution  
30%/0.8% 
bisacrylamid 
 3.75 ml TRIS-base pH 8.0 
 0.15 ml SDS-10% 
 6.1 ml Aqua dest. 
 15 µl TEMED 
 75 µl APS 10% 
Stacking gel 1.7 ml PAA solution  
30%/0.8% 
bisacrylamide 
 1.0 ml TRIS-HCl pH 6.8 
 0.1 ml SDS 10% 
 7.0 ml Aqua dest. 
 20 µl TEMED 
 100 µl APS 10% 
Coomassie staning 
solution 
1.5 g Coomassie brilliant 
blue R250 
 50 ml Acidic acid (100%) 
 225 ml EtOH (96%) 
 ad 500 ml Aqua dest. 
37 
 
 
Coomassie 
destaining solution 
100 ml Acidic Acid (100%) 
 333 ml EtOH (96%) 
 ad 1000 ml Aqua dest. 
Luminol (stock 
solution) 
0.44 g Luminol 
 ad 10 ml DMSO 
p-coumaric acid  
(stock solution) 
0.15 g p-coumaric acid 
 ad 10 ml DMSO 
ECL (homemade) 4.5 ml Aqua dest. 
 0.5 ml TRIS-base, 1M pH 
8.5 
- prior to use 25 µl Luminol (stock 
solution) 
 11 µl p-coumaric acid  
(stock solution) 
 1.5 µl H2O2 (30%) 
Membrane 
stripping solution 
0.11 M Glycine 
 1% (v/v) SDS 
  in 0.1M HCl  
 
 
Solution for flow cytometry   
FACS buffer pH 7.37 8.12 g NaCl 
 0.26 g KH2PO4 
 2.35 g Na2HPO4 
 0.28 g KCl 
 0.43 g LiCl 
 0.2 g Na2N3 
 0.36 g Na2EDTA 
 ad 1000 ml Aqua dest. 
HBSS buffer pH 7.4 8.18 mg NaCl 
 400 mg Kcl 
 19.75 mg Na2HPO4 
 50 mg KH2PO4 
 180 mg CaCl2 . 2H2O 
 97.5 mg MgSO4 
 1000 mg Glucose 
 4760 mg HEPES 
 ad 1000 ml Aqua dest. 
Table VIII : Solutions 
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1.6 Other Equipment 
 
 
Miscellaneous material  
Name Provider 
Precision Plus Protein Standard BIO-RAD Laboratories (Hercules, Ca, USA) 
Gel blotting paper Whatman plc (Kent, UK) 
Table IX: Miscellaneous material 
 
 
Technical Equipment  
Name Provider 
Vi-Cell XR Cell Viability Analyzer Beckman Coulter (Fullerton, Ca, USA) 
Tecan GENios Pro, Tecan Sunrise Tecan (Mannedorf, Switzerland) 
LAS-3000 Luminescent Image Analyzer Fujifilm (Tokyo, Japan) 
Power Supply Power Pack HC BIO RAD Laboratories  
(Hercules, Ca, USA) 
Mini Trans-Blot Electrophoretic Transfer 
Cell 
BIO RAD Laboratories  
(Hercules, Ca, USA) 
FACSCalibur BD Biosciences Pharmingen  
(San Diego, Ca, USA) 
Light Microscope Olympus CKX 31 Olympus Europa GmbH  
(Hamburg, Germany) 
Table X: Technical Equipment  
 
 
EDV Software  
Name Provider 
AIDA (Advanced Image Data Analyzer) 
version 4.06 
raytest GmbH (Straubenhardt, Germany) 
GraphPad PRISM version 4.03 GraphPad Software, Inc.  
(San Diego, Ca, USA) 
Image Reader LAS-3000 version 2.0 Fujifilm (Tokyo, Japan) 
Vi-Cell XR 2.03 Beckman Coulter (Fullterton, Ca, USA) 
Table XI: EDV Software 
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2 Methods 
 
2.1 Cell Culture 
 
2.1.1 Cultivation of cells 
 
Vascular Smooth Muscle Cells (VSMC), extracted from male Sprawgue Dawley rat 
thoracic aortas were used for all experiments. 
Cells were cultivated in 75 cm2 flasks at +37º C and 5% CO2. Phenol-red free 
Dulbecco´s modified Eagle´s medium with 10% calf serum, 2 mM Glutamine, 100 
U/ml Penicillin and 100 µm/ml Streptomycin was used as growth medium. Cells were 
grown to nearly 90% confluence.  
 
2.1.2 Passaging the cells 
 
After reaching a confluence of about 90%, cells were harvested with Trypsin/EDTA, 
pelleted by centrifugation (10 min, 1100 rpm, 4º C) and resuspended in growth 
medium. Afterwards cells were counted in a ViCell. With Trypan blue staining, the 
level of viable cells was determined. Approximately 2 x 106 cells were seeded in a 75  
cm2 flask.  
For experiments, only cells between passage 7 and 14 were used.  
 
2.1.3 Light microscopy 
 
Cells were checked during the growth period regularly via light microscopy for status 
of confluence and abnormal varieties. 
 
2.1.4 Preparing cells for experiments 
 
Stimulation of cells was carried out either in 6-well plates or in 60 mm dishes. Cells 
were seeded after passaging, reaching a confluence of approx. 80-90% on the day of 
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the experiment. 24 h before the experiment, cells were rendered quiescent by 
incubation with DMEM without CS.  
 
2.1.5 Stimulation of cells 
 
Before stimulating the cells the CS-free DMEM was replaced by fresh, CS-free  
medium, then the preincubation with Indirubin 3´monoxime (I3MO) was done at 
concentrations, indicated in the results section. Control cells, which represent the 
quiescent status, were treated the same way, containing only the vehicle (DMSO 
1%). After 30 minutes of incubation, a time course of PDGF (20 ng/ml) stimulation 
was performed. In defined time intervals from 2 minutes to 10 minutes PDGF was 
added to the dishes (2´ 5´ 7´ 10´ minutes). 
 
To terminate the stimulation, cells were washed twice with ice cold PBS and then 
lysed with lysis buffer containing phosphatase and protease inhibitors for 30 min at 4º 
C. The cell residues were scrapped off from the plate and transferred into pre-cooled 
eppendorf-tubes, then centrifuged at 13000 rpm for 10 min at 4º C. 
 
A small amount of the cell-lysate was put aside for determination of the protein level 
in each plate with the Bradford Assay. The rest was diluted with 3x SDS sample 
buffer containing bromphenol blue and boiled at 95º C for 5 minutes. Then it was 
stored at -20º C.  
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2.2 Preparation of cell lysates for Western Blotting 
 
2.2.1 Protein level quantification 
 
The quantification of the protein level in the obtained cell lysates was examined with 
the method of Bradford. This method is based on the fact that the maximal 
absorbance of a Coomassie blue solution shifts from 470 nm to 595 nm when binding 
to basic, aromatic amino acid residues.  
 
The small probes of the cell lysates kept aside for protein quantification were diluted 
1:10 with aqua bidest. 10 µl of each lysate sample were put in triplicate on a 96 well 
plate and filled up to 200 µl with Bradford Solution. Together with the samples, 10 µl 
of a calibration standard with an increasing concentration of BSA was brought up on 
the plate, consisting of 50-500 µg/ml Bovine Serum Albumine (BSA)  in aqua bidest.  
Then the wells were filled up with 190 µl Bradford Solution.  
 
After applying the cell lysates and the calibration standards, the 96-well plate was 
incubated for 5 minutes. Then the absorbance was measured with a Tecan Sunrise 
microplate reader at 595 nm.  
2.2.2 SDS PAGE 
 
Cell Lysates were separated by electrophoresis on a discontinous SDS-PAGE 
(sodium dodecyl sulphate-polyacrylamide gel electrophoresis), according to Laemmli. 
 
This method uses SDS, an anionic detergent to destroy the 3D structure of the 
proteins and polypeptides by binding to hydrophobic regions of the molecule. 
Furthermore, disulfid bonds are cleaved by treatment with reducing agents such as 
DTT (Dithiothreitol). SDS is added in surplus, so that the detergent covers the whole 
protein with a negative charge. Therefore the final separation is based on the 
molecular weight of the proteins and peptides. 
 
Two kinds of gel layers were prepared to carry out the SDS-PAGE. The first layer 
concentrates cell lysates to an ultrathin zone (stacking gel) while the second layer 
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(running gel), finally separates proteins. These gel layers differ in their amount of 
PAA and therefore in the density of the acrylamide mesh. Gels were formed out of a 
solution of 30% PAA/0,8% Bisacrylamide. The PAA concentration is chosen in a way 
that finally the proteins of interest are separated clearly in the middle of the running 
gel, while other proteins, lighter or heavier in their molecular weight, will not be 
separated or even run out of the gel.  
 
Equal amounts of proteins were applied in preformed pockets in the stacking layer. 
Electrophoresis was driven then by a Mini-PROTEAN 3 cell system connected to a 
PowerPac HC Power supply at 110 V for 21 minutes to stack the proteins and then 
at 200 V for 36 minutes for separation. 
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2.3 Western blotting  
 
2.3.1 Transfer to membranes and protein detection 
 
After the separation of the proteins, the resulted protein bands were transferred to a 
PVDF membrane using western blot with tank blotting technique. Proteins were 
transferred for 90 min at 100 V with a Mini Trans-Blot electrophoretic transfer cell 
system.  
 
After the transfer was finished, the PVDF membranes were blocked with 5% fat free 
milk powder in TBS-T for approx. 1 h. The blocking solution was then washed off and 
the primary antibody was applied for an overnight incubation at 4º C. To make sure 
that the proteins were loaded equally, the gel layers were stained seperately with 
Coomassie staining solution.  
 
The next day the membrane was washed three times with TBS-T and the secondary 
horseradish-peroxidase conjugated antibody was applied for 3 hours at room 
temperature. The membrane was washed another tree times with TBS-T and then 
Protein detection was carried out with a LAS-3000 luminescent image analyzer 
using ECL solution. Separated protein bands were quantified with AIDA software 
using α-Tubulin as a loading control. 
 
2.3.2 Stripping of membranes 
 
In order to detect more than one protein on one membrane, the used antibodies can 
be stripped off with membrane stripping solution.  
 
First the membrane was washed in Aqua dest. for 10 min and then it was treated with 
membrane stripping solution for 15 min on a shaking platform at room temperature. 
Afterwards it was washed three times with TBS-T and then blocked with 5% fat free 
milk powder in TBS-T for one hour. New antibodies were brought up on the 
membrane as described above.  
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2.3.3 Staining of gels 
 
To make sure that the proteins were loaded equally on the gel layers, the gel 
residues were stained with Coomassie blue after carrying out western blotting.  
Resolving gel residues were put in a Coomassie blue dying solution on a shaking 
platform for 20 minutes at room temperature until the dying agent was penetrated 
into the gel layer. Afterwards the gel residue was washed in TBS-T until the protein 
bands appear as blue strips against a transparent ground. 
 
2.4 Flow Cytometry 
 
2.4.1 Technical and physical basics 
 
Flow cytometry is based on the emission of optical signals by cells or cell particles 
when they pass a beam of laser light. Therefore cells are brought in a capillary, 
where they pass the beam one by one at high speed, so that detections can be made 
in real time. Flow Cytometry can distinguish cells by their relative size and their 
relative granularity. Detection can also be done by flourescent agents and the 
measurement of flourescence intensity. The technique is e.g. used for cell cycle 
analysis, cell death measurement and apoptosis, membrane potential measurement, 
expression of proteins and surface antigens and measurement of oxidative burst.  
 
When a cell or a cell particle passes a laser beam it scatters the light in several ways. 
Hereby the amout of scattered light correlates with the size and the complexity of the 
cell. 
The Forward Scatter (FSC) detects the light that is bended by the cell along the 
beam, representing a measure for the volume of the cell. The Sideward Scatter 
(SSC) detects the light fractions scattered at right angle to the laser beam, 
representing a measure for granularity. The gained signals are detected and 
processed by a computer system. 
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Parallel to the measurement of scattered light, flurescence measurement can be 
done. Therefore a flourescent agent is brought up on the cells, binding to specific 
cellular components and allowing quantitative measurement of these components. 
Common flourescent agents are DAPI (4´,6-diamino-2-phenylindole), used in virus 
detection, Propidiumiodide for detection of viability or H2DCF-DA. Also antibodies, 
carrying flourescent groups are used. With different flourescenting dyes and filters 
and the use of lasers of different colours a big variety of gained information can be 
reached. 
 
All flow cytometric investigations were performed on a FACSCalibur by illuminating 
the cells with an argon laser (488 nm). H2DCF-DA was used as a flourescence 
agent. 
 
2.4.2 ROS measurement 
 
2´,7´-dichloro-dihydroflourescein-diacetate (H2DCF-DA) was used as a flourescence 
dye to detect ROS generation in VSMC. The reagent is brought up on the cells in a 
non flourescent, non reactive diacetate form. After passing the cell membrane, the 
diacetate is cleaved via cellular esterases to H2DCF. This molecule is prone to 
oxidation by reactive oxygen species and thereby transformed in DCF which is a 
flourescent agent.  
 
Cells were seeded at 0.25 x 106 cells/well and kept in growth medium for two days. 
24 h before the measurement, cells were set on medium without CS. Wells were 
washed with HBSS at 37 ºC and then equilibrated with HBSS. Cells were either 
preincubated with I3MO (3 µM), vehicle (1% DMSO) or left untreated. 15 minutes 
later, H2DCF-DA was added to the cells and another 15 minutes later, cells were 
stimulated with PDGF-BB (20 ng/ml) for 10 minutes. Due to the light sensitivty of 
DCF, all of these processes had to be performed in a darkened laboratory. After 
sucking off the buffer and washing, the cells were trypsinised and the stimulation was 
stopped with BSA 2% in PBS. Immediately after harvesting, cells were brought to the 
flow cytometer and the geo mean of flourescence intensity was recorded.  
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2.5 Statistics 
 
All experiments were performed at least three times. Data are expressed as means ± 
SEM. Statistical analysis was evaluated by one-way ANOVA followed by a Bonferroni 
multiple comparison test. In case of time courses, treatment with or without I3MO at 
each time point was compared using one-tailed paired t-test. P values < 0.05 were 
considered significant. All tests were performed using GraphPad PRISM™ software 
version. 
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C RESULTS 
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1 Impact of Indirubin 3´- monoxime on the phosphorylation of the 
Kinases ERK1,2 and AKT   
 
 
1.1 Stimulation with PDGF 
 
Stimulation of VSMC with PDGF leads to an increase in phosphorylation on 
Serine/Threonine Kinase AKT and on MAP-Kinases ERK1,2. These kinases are 
reported to be involved in PDGF-induced proliferation [101, 117, 118]. It is accepted 
that phosphorylation of these kinases is a sign of activation [119, 120]. We therefore 
stimulated cells in a time course and revealed the phosphorylation level of the 
kinases by western blotting with phospho-specific antibodies. For reference we left 
cells untreated in CS-free medium.  
 
As shown in Figure XII and XIII, PDGF leads to a strong and fast increase in 
phosphorylation of AKT and ERK1,2 after 2 minutes which does not alter significantly 
during the whole time course up to 10 minutes.  
 
 
 
1.2 Treatment with I3MO 
 
Previous experiments in our lab showed a delay in phosphorylation of AKT and 
ERK1,2 in response to I3MO, but there was finally no marked reduction in activation 
of these kinases detectable [2]. In our experiments we could confirm that there is not 
any significant reduction in phosphorylation of the MAP Kinases ERK1,2  and  AKT in 
the presence of I3MO, as seen in Figure XII and XIII.  
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Blots and Graphs for pAKT 
       I3MO 
 
        PDGF       -        2   5    7    10         2     5    7   10 min 
 
 
 
 
 
 
                                
Figure XII 
VSMC were grown to near confluence and kept in CS-free medium for 24 hours. They were 
incubated with I3MO (3 µM) for 30 minutes or with DMSO (1%) only. After incubation a time 
course was driven by stimulating the cells for 2, 5, 7, 10 minutes with PDGF-BB (20 ng/ml). As 
reference cells were left untreated. After western blotting the protein level of pAKT was 
detected with a phospho-specific antibody as described in the methods section. Tubulin was 
used as a loading control.  
n.s. = not significant (P > 0.05) Graphs show averaged data of three independent 
experiments. (paired t-test, PDGF versus PDGF + I3MO) 
 
 
 
pAKT 
Tubulin 
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Blots and Graphs for ERK1,2 
 
 
 
PDGF             -      2     5      7    10     2     5     7    10 min                  
 
 
 
 
Figure XIII 
VSMC were grown to near confluence and kept in CS-free medium for 24 hours. They were 
incubated with I3MO (3 µM) for 30 minutes or DMSO (1%) only. After incubation a time course 
was driven by stimulating the cells for 2, 5, 7, 10 minutes with PDGF-BB (20 ng/ml). As 
reference cells were left untreated. After western blotting the protein level of pERK1 and 
pERK2 was detected with a phospho-specific antibody as described in the methods section. 
Tubulin was used as a loading control. n.s. =  not significant (P > 0.05) Graphs show averaged 
data of three independent experiments. (paired t-test, PDGF versus PDGF + I3MO) 
Tubulin 
pERK1,2 
 + I3MO  
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2 Influence of Indirubin on PDGF Receptor Phosphorylation 
 
 
2.1 PDGF-induced autophosphorylation 
 
It is generally accepted, that binding of the PDGF dimer leads to dimerization and 
further transphosphorlyation of two receptor monomers [101]. In our experiments we 
could show, according to previous tests, [2] that PDGF leads to a strong increase in 
phosphorylation on Y579/581.  
 
2.2 Treatment with I3MO 
 
Previous experiments in our lab showed a reduction of phosphorylation of Y579/581 in 
the presence of Indirubine 3-monoxime [2]. Our experiments could also show a 
significant reduction in phosphorylation at 5 min. However, in contrast to prior 
experiments other time points failed to be significant.  
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              PDGF      –     2     5      7    10     2     5      7    10 min 
 
 
 
 
 
 
Figure XIV 
VSMC were grown to near confluence and  kept in CS-free medium for 24 hours. They were 
incubated with I3MO (3 µM) for 30 minutes or with DMSO (1%) only. After incubation a time 
course was driven by stimulating the cells for 2, 5, 7, 10 minutes with PDGF-BB (20 ng/ml). As 
reference, cells were left untreated.  After western blotting the phosporylation level of PDGF-R 
Y579/581 was detected with a phospho-specific antibody as described in the methods 
section.Tubulin was used as a loading control.  
* = P < 0.05 n.s. = not significant (P > 0.05) Graphs showa veraged data of three independent 
experiments. (paired t-test, PDGF-BB versus PDGF-BB + I3MO) 
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3 Influence of Indirubin 3´-monoxime on ROS mediated signalling  
 
 
Prior experiments in our lab led to the hypothesis that Indirubin 3´-monoxime acts on 
STAT via reduction of intracellular ROS. Experiments with N-Acetyl Cystein (NAC), a 
precursor of glutathion -an important cellular antioxidant-, were performed to 
elucidate the influence of ROS on targets of several pathways involved in PDGF 
induced proliferation.  
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3.1 Impact of Indirubin 3´-monoxime on the kinases ERK1,2 compared to 
the Antioxidant NAC 
 
 
  
 
 
 
 
 
 
 
Figure XV 
VSMC were grown to near confluence and kept in CS-free medium for 24 hours. They were 
pretreated with NAC (10 mM) for one hour, giving time to synthesize glutathion as an 
antioxidant. As reference cells were left untreated. 30 minutes before stimulation I3MO (3 µM) 
was added. Stimulation was performed for 10 minutes with PDGF-BB (20 ng/ml). After 
western blotting the phosporylation level of Erk1,2 was detected with a phospho-specific 
antibody as described in the methods section. Tubulin was used as a loading control. Graphs 
show averaged data of three independent experiments. (one-way ANOVA versus PDGF-BB 
treatment) *** = P<0.001, n.s. =  not significant (P > 0.05) 
 
pERK1 
pERK2 
Tubulin 
 + NAC 
PDGF        -           +           -           +           -           +          -           + 
I3MO          -           -           +          +           -            -          +          +  
PDGF              -       +       -       +        -      +       -        + 
I3MO                -       -       +       +       -       -       +       +  
+NAC 
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3.1.1 Impact of NAC on ERK1,2 activation  
 
Treatment with PDGF leads to a strong phosphorylation of ERK Kinases which is not 
affected by the presence of NAC.  
 
3.1.2 Impact of I3MO on ERK1,2 compared with NAC  
 
In the presence of I3MO the induction of phosphorylation by PDGF is, according to 
previous findings, not significantly reduced. Also the presence of NAC together with 
I3MO does not influence the activation of ERK1,2.  
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3.2 Impact of Indirubin 3´-monoxime on AKT Kinase compared to the 
Antioxidant NAC 
 
         
          
 
 
 
 
 
  
 
 
Figure XVI 
VSMC were grown to near confluence and kept in CS-free medium  for 24 hours. They were 
pretreated with NAC (10mM) for one hour, giving time to synthesize glutathion as an 
antioxidant. As reference cells were left untreated. 30 minutes before stimulation I3MO (3 µM) 
was added. Stimulation was performed for 10 minutes with PDGF-BB (20 ng/ml). After 
western blotting the phosporylation level of pAKT was detected with a phospho-specific 
antibody as described in the methods section.Tubulin was used as a loading control. Graphs 
show averaged data of three independent experiments. (one-way ANOVA versus PDGF-BB 
treatment)   
*** = P < 0.001, n.s. = not significant (P > 0.05) 
pAKT 
Tubulin 
 + NAC 
PDGF        -             +           -            +           -           +            -           + 
I3MO          -             -           +           +           -            -            +          +  
PDGF              -       +       -       +        -      +       -        + 
I3MO                -       -       +       +       -       -       +       +  
+NAC 
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3.2.1 Impact of NAC on AKT activation 
 
Treatment with PDGF leads to a strong phosphorylation of AKT Kinase, which is not 
affected by the presence of NAC.  
 
3.2.2 Impact of I3MO on AKT compared with NAC 
 
In the presence of I3MO the induction of phosphorylation is, according to prior 
findings, not significantly reduced. Also the presence of NAC together with I3MO 
does not influence the activation of AKT. 
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3.3 Impact of Indirubin 3´-monoxime on STAT3 compared to the    
Antioxidant NAC 
 
    
     
 
 
 
 
 
 
Figure XVII 
VSMC were grown to near confluence and kept in CS-free medium  for 24 hours. They were 
pretreated with NAC (10mM) for one hour, giving time to synthesize glutathion as an 
antioxidant. As reference cells were left untreated. 30 minutes before stimulation I3MO (3 µM) 
was added. Stimulation was performed for 10 minutes with PDGF-BB (20 ng/ml). After 
western blotting the phosporylation level of pSTAT3 was detected with a phospho-specific 
antibody as described in the methods section.Tubulin was used as a loading control. Graphs 
show averaged data of three independent experiments. (one-way ANOVA versus PDGF-BB 
treatment)  
* = P < 0.05, n.s. = not significant (P > 0.05) 
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3.3.1 Impact of NAC on STAT3 activation  
 
Treatment with PDGF leads to a strong increase in STAT3 phosphorylation, which 
appears reduced in the presence of NAC. However, data are not statistically 
significant.  
 
3.3.2 Impact of I3MO on STAT3 compared with NAC 
 
In the presence of I3MO the phosphorylation of STAT3 in response to PDGF is, 
according to previous findings, significantly reduced. The presence of NAC does not 
reveal any significant synergistic effects in reducing phosphorylation level of STAT3.  
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3.4 Impact of Indirubin 3´-monoxime on PDGF receptor 
autophosphorylation compared to the Antioxidant NAC 
 
    
        
             
 
 
 
 
 
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         
 
 
Figure XVIII 
VSMC were grown to near confluence and kept in CS-free medium  for 24 hours. They were 
pretreated with NAC (10mM) for one hour, giving time to synthesize glutathion as an 
antioxidant. As reference cells were left untreated. 30 minutes before stimulation I3MO (3 µM) 
was added. Stimulation was performed for 10 minutes with PDGF-BB (20 ng/ml). After 
western blotting the phosporylation level of PDGF receptor Y579/581 was detected with a 
phospho-specific antibody as described in the methods section.Tubulin was used as a loading 
control. Graphs show averaged data of three independent experiments (one-way ANOVA 
versus PDGF-BB treatment)  * = P < 0.05 n.s. = not significant (P>0.05) 
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3.4.1 Impact of I3MO on PDGF receptor phosphorylation  
 
Treatment with PDGF leads to a strong increase in PDGF receptor 
autophosphorylation, which appears reduced in the presence of NAC. However, data 
were not statistically significant. 
 
3.4.2 Impact of I3MO on PDGF receptor phosphorylation compared to NAC  
 
In the presence of I3MO the autophosphorylation of the PDGF receptor in response 
to PDGF is, in contrast to prior findings, not significantly reduced. The presence of 
NAC does not reveal any significant synergistic effects in reducing PDGF-R 
phosphorylation level, although the standard error of the mean at I3MO + NAC is too 
high to make clear statements.  
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3.5 Effect of Indirubin 3´-monoxime on the level of Reactive oxygen 
Species 
 
Western Blot data from previous experiments suggested an influence of Indirubin 3´- 
monoxime on STAT3 (not shown) and PDGF Receptor phosphorylation. The 
influence of Indirubin 3´-monoxime could be mediated via protein tyrosin 
dephosphorylating phosphatases, which are regulated in their activity via ROS.  
 
In order to check the Influence of Indirubin 3´-monoxime on ROS level, we set up a 
flow cytometric experiment in which reactive oxygen species were quantified by the 
flourescent agent  H2DCF. Although the data did not reach significance the PDGF-
triggered flourescence after treatment with Indirubin 3´-monoxime appears to be 
reduced. (Figure XIX) 
 
Previous experiments with Indirubin 3´-monoxime even showed a reduction of 
reactive oxygen species when I3MO is added at the time of PDGF stimulation 
instead of beeing added 15 minutes prior to stimulation [2]. 
 
3.5.1 Time-dependent Impact of I3MO on Reactive Oxygen Species Level 
 
Using DCF and flow cytometry, we measured the flourescence in VSMC, which 
correlates to the level of intracellular ROS. Indirubin was again added at different 
timepoints with regard to PDGF stimulation in order to evaluate probable 
mechanisms of action.  
 
1) Indirubin-3´monoxime added 15 minutes before stimulation with PDGF 
2) Indirubin-3´monoxime added simultanously with stimulating PDGF 
3) Indirubin-3´monoxime added 5 minutes after PDGF stimulation 
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Figure XIX 
VSMC were grown to near confluence and kept in CS-free medium  for 24 hours. They were 
pretreated with I3MO (3 µM) or vehicle (DMSO 1%) for 15 min. H2DCF (20 µM) was added 
and cells were incubated for another 15 min. Stimulation was performed for 10 minutes with 
PDGF-BB (20 ng/ml). I3MO (3 µM) was also added simultanously with PDGF-BB stimulation 
or 5 minutes afterwards. Flow cytometry was performed right afterwards as described in the 
methods section. Graphs show averaged data of four independent experiments performed in 
triplicate. (one-way ANOVA versus PDGF-BB treatment) n.s. = not significant (P > 0.05)  
 
 
 
Although the results did not reach significance, there was a tendency towards a 
reduced ROS level after I3MO incubation prior to PDGF stimulation. If Indirubin 3´-
monoxime is added simultanously to PDGF, reduction holds on. Even if Indirubin is 
added 5 minutes after PDGF stimulation, a reduction of ROS is visible, possibly 
pointing to targets for Indirubin which are involved in signalling processes occurring 
up to 5 minutes after PDGF stimulation. 
 
PDGF             -             +             -          +              -            +            -             + 
I3MO              -              -             +          +             +           +            +            + 
2) I3MO simultanously  
with PDGF 
3) I3MO 5 min 
after PDGF 
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3.5.2 Impact of I3MO on ROS level compared to NAC 
 
In the following setting, the measurement of ROS level in VSMC was performed in 
the presence of I3MO as well as in the presence of NAC. The aim of this experiments 
was to determine if the effect of Indirubin could also be achieved by adding NAC, a 
known antioxidant.  Furthermore we added NAC together with I3MO in order to check 
synergistic effects. Previous experiments excluded a direct antioxidative, radical 
scavenging action of Indirubin on ROS [2]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure XX 
VSMC were grown to near confluence and kept in CS-free medium  for 24 hours. They were 
pretreated with NAC (10mM) for one hour, giving time to synthesize glutathion. I3MO (3 µM) 
or vehicle (DMSO1%) was added 15 min before stimulation. Stimulation was performed for 10 
minutes with PDGF-BB (20 ng/ml). Flow cytometry was performed right afterwards as 
described in the methods section. Graphs show averaged data of four independent 
experiments.  
(one-way ANOVA versus PDGF-BB treatment) n.s. = not significant (P > 0.05) 
PDGF            -            +             -             +             -             +             -               + 
I3MO             -             -             +            +             -              -             +              + 
NAC               -             -             -             -              +            +             +              + 
n.s. I3MO 
NAC 
I3MO & NAC 
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D Discussion 
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1 Influence of I3MO on phosphorylation of Kinases AKT and ERK1,2 
 
The stimulation of VSMCs with PDGF leads to an increase in the phosphorylation on 
Serine/Threonine kinase AKT and the MAP Kinase ERK1,2. It is accepted that 
phosphorylation of these kinases is a sign of activation [119, 120]. The activation of 
the PI3K/AKT pathway as well as the MAP-Kinase pathway is related to cell 
proliferation and migration [101, 117]. Prior experiments in our group showed that 
there is no influence of I3MO on the PDGF-mediated increase in phosphorylation of 
these kinases [2]. As shown in Figure XII and XIII, we could confirm previous results, 
showing that there is no influence on the phosphorylation of these kinases from 
I3MO. 
 
I3MO seems not to mediate its negative effect on cell proliferation via inhibition of the 
phosphorylation of PDGF-activated Kinases AKT and ERK1,2. 
 
2 Influence of I3MO on phosphorylation of STAT3 transcription 
factor 
PDGF is also known to induce the activation of the JAK/STAT pathway [95]. Previous 
findings in our lab showed a significant reduction of the PDGF-induced 
phosphorylation of STAT3 by I3MO. We also wanted to confirm these findings, but 
for unknown reasons our experiments failed to produce usable results. 
 
3 Influence of I3MO on phosphorylation of the PDGF receptor 
It is generally accepted, that PDGF receptor activation leads to association of two 
PDGF receptor monomers and further transphosphorylation [63]. We examined the 
phosphorylation on PDGF receptor Y579/581. As previous experiments in our group 
showed, I3MO seems to have a diminishing effect on phosphorylation of these 
tyrosin residues, as well as on the overall phosphorylation of the receptor [2]. 
As shown in Figure XIV, treatment with Indirubine 3´-monoxime leads to a visible and 
reproducible reduction of the phosphorylation on Y579/581, although, in contrast to 
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previous findings, the results lack to be significant in most of the timepoints. Possible 
reasons for the unsignificant results could be the great variation between the 
individual experiments. This variance, which is not unusual for cell-based model 
systems, results in huge standard deviations.  
 
4 Influence of Indirubin 3´-monoxime on ROS-mediated signalling 
Reactive oxygen species as second messengers are known to be involved in PDGF 
signal transduction, because several PDGF-related pathways are reported to require 
ROS [111, 112, 121, 122]. This led to the hypothesis that I3MO acts on PDGF 
signalling via influencing the signal transduction by modulating levels of reactive 
oxygen species. 
 
Experiments, done with N-Actetyl Cystein, a precursor of the intracellular antioxidant 
glutathion, should reveal, whether the effect of I3MO on kinase pathways, as well as 
on STAT3 transcription factor could be mimiked by an antioxidant. As shown in 
Figures XV and XVI, the presence of NAC does not have any inhibitory effect on the 
PDGF-mediated phosphorylation of the Kinases AKT and ERK1,2. This correlates 
with the previous findings, that I3MO has no influence on these kinases. (See figures 
XII and XIII) 
 
The effect of NAC on PDGF-mediated activation of STAT3 is shown in Figure XVII. 
Although the results do not reach significance, there is a tendency towards reduced 
levels of phosphorylated STAT3 in the presence of NAC as well as in the presence of 
I3MO.  
 
Taking into account, that I3MO affects the kinases AKT and ERK1,2 as well as the 
STAT3 transcription factor in the same way as NAC, the presumption can be raised, 
that I3MO indeed exerts its effect by influencing the level of reactive oxygen species. 
This is in line with previous findings, showing that inhibition of ROS by the NADPH 
oxidase inhibitor DPI reduces STAT3 phosphorylation [2].  
 
The influence of NAC on PDGF receptor Y579/581 transphosphorylation is also 
comparable to the influence obtained with I3MO. As Figure XVIII shows, 
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phosphorylation of Y579/581 appears to be reduced in the presence of I3MO as well as 
in the presence of NAC (although not significant). This datas together with previous 
results [2], suggests an influence of ROS on regulation of PDGF receptor 
phosphorylation, as well as a possible mechanism of I3MO similar to NAC. Potential 
targets influenced by modulated ROS levels are phosphotyrosine phosphatases. 
 
5 Influence of I3MO on ROS production 
Previous flow cytometric experiments to examine the influence of I3MO on PDGF-
triggered elevation in intracellular ROS production were repeated [2]. In order to put 
light on probable mechanisms of action of I3MO on PDGF receptor-signalling. I3MO 
was added at three different timepoints. In all experiments cells were treated with 
I3MO 15 minutes prior to, simultaneously with and 5 minutes after PDGF stimulation, 
respectively. 
 
Figure XIX shows, a visible reduction in PDGF-triggered ROS production after 
incubation with I3MO. In all settings, even application of I3MO simultaneously and 5 
minutes after stimulation led to a visible decrease of ROS production. However, the 
results did not reach significance. This is maybe due to the low increase in ROS after 
PDGF treatment in comparison to the basal level of ROS. 
 
6 Influence of I3MO on ROS production in the presence of NAC 
Further we wanted to determine, wether the effect of I3MO on PDGF-triggered ROS 
production could also be achieved by an antioxidant and if this effect is similar  to 
I3MO. Prior experiments excluded a direct antioxidative, radical scavenging action of 
indirubin [2].  
 
In these flow cytometric experiments we incubated cells with I3MO, NAC and also 
applied both substances together, in order to reveal any synergistic effect. As seen in 
figure XX, the antioxidant NAC implemented almost the same effect on PDGF-
treated cells like NAC. Applying NAC and I3MO together revealed no synergistic 
effect.  
 
69 
 
7 Concluding remarks and outlook 
 
Overall, we could confirm previous data, that I3MO does not affect PDGF-induced 
ERK1,2 and AKT phosphorylation, but inhibits STAT3 phosphorylation and dampens 
PDGF receptor phosphorylation. I3MO may decrease PDGF-induced ROS formation 
up to 5 minutes after stimulation. I3MO mimics the effect of NAC, a known 
antioxidant, with regard to MAPK-, AKT- and STAT phosphorylation and ROS 
production, which highlights ROS as a potential target of I3MO. Synergistic action of 
NAC and ROS could not be observed.  
Indirubin and its derivatives inhibit proliferation of VSMC and could be used in 
various therapeutic applications. In a cuff-induced neointimal formation mouse model 
for example could be shown, that I3MO reduces the formation of a neointima in 
mouse arteries [2]. In order to optimize the chemical structure or find derivatives with 
a better pharmacodynamic profile than Indirubin 3´-monoxime, it is necessary to 
elucidate the molecular mechanism of its antiproliferative action. Further experiments 
should determine how Indirubin 3´-monoxime acts on intracellular ROS production, 
and how this influence is linked with the STAT3 phosphorylation and the cell cycle 
machinery. 
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A Abbreviations 
 
In alphabetical order 
 
A 
AhR  Aryl hydrocarbon Receptor 
ATII  Angiotensin II 
 
C 
c-Fos  DNA binding transcription factor 
c-Jun  DNA binding transcription factor 
c-Myc  DNA binding transcription factor 
CYP P450 Cytochrome P450 Enzyme Family   
 
D 
DEP  Phosphotyrosin Phosphatase 
DTT  Dithiothreitol 
 
E 
EGF  Epidermal growth factor 
ELK1  Ets Like gene1 – transcription factor 
 
F 
FGF  Fibroblast growth factor 
 
G 
GAP  GTPase activating proteins 
GDP  Guanosine Diphosphate 
GEF  Guanine nucleotide exchange factor 
Grb2  Adaptor protein involved in Cytokine signalling 
GSK-3  Glycogen Synthase Kinase 3 
GTP  Guanosine Triphosphate  
 
I 
I3MO  Indirubine 3´-monoxime 
IFNγ  Interferon gamma 
IGF1  Insuline-like growth factor 
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IL-6  Interleukin (-6) 
 
J 
JAK  Tyrosin kinase – Just Another Kinase/Janus Kinase  
JNK  c-Jun N-terminal kinases 
 
M 
MAPK  Mitogen Activated Protein Kinase 
 
N 
NADPH Nicotinamide Adenine Dinucleotide Phosphate 
NFκB  Nuclear Factor κB 
NOX  NADPH Oxidase 
 
P 
PAA  Polyacrylamide 
PAGE  Polyacrylamide gel electrophoresis 
PCB  Polychlorinated biphenyls 
PCTA  Percutaneus transluminal coronary angioplasty 
PDGF  Platelet derived Growth factor 
PIAS  Protein Inhibitors of activated STAT 
PI3K  Phosphoinositide 3-kinase  
PTEN  Phosphatase and tensin homolog – a phosphatase 
PTP1β  Phosphotyrosin Phosphatase 
PVDF  Polyvinylidenflouride 
 
R 
Rac  small GTPases – Subfamily of Rho family of GTPases 
Raf1  Serine/Threonine specific kinase 
Ras  small GTPase   
ROS  Radical Oxigen Species 
 
S 
SH  Src homology Domain 
SHIP  Phosphatase 
SDS  sodium dodecyl suphate 
SDS-Page sodium dodecyl sulphate – polyacrylamide gel electrophoresis 
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SOCS  Supressor of Cytokine signalling 
SOD  Superoxide dismutase 
SOS1  “Son of Sevenless” protein  
Src  Tyrosin kinase –named after similar kinases found in  “Rous Sarcoma Virus” 
STAT  Signal Transducers and activator of transcription 
 
T 
TBS-T  Tris-buffered saline containing – Tween 20 
TC-PTP T-Cell Phosphotyrosin Phosphatase 
TGFβ  Transforming growth factor 
TNFα  Tumor necrosis factor 
 
V 
VSMC  Vascular Smooth Muscle Cells 
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